MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC

• Egile Nagusiak: Renumathy Dhanasekaran (Egilea), Jangho Park (Egilea), Alekesey Yevtodiyenko (Egilea), David I. Bellovin (Egilea), Stacey J. Adam (Egilea), Anand Rajan KD (Egilea), Meital Gabay (Egilea), Hanan Fernando (Egilea), Julia Arzeno (Egilea), Vinodhini Arjunan (Egilea), Sergei Gryanzov (Egilea), Dean W. Felsher (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2020-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The MYC oncogene is dysregulated in most human cancers and hence is an attractive target for cancer therapy. We and others have shown experimentally in conditional transgenic mouse models that suppression of the MYC oncogene is sufficient to induce rapid and sustained tumor regression, a phenomenon...